ClinicalTrials.gg
RecruitingNCT07056075PrePAP-ERCPUpdated Mar 24, 2026

Prevention of Desaturations Using Positive Airway Pressure or Capnometry During ERCP

An interventional study of Nasal PAP Ventilation System and Low Flow Oxygen in Desaturation, Hypoxemia and ERCP, sponsored by Karl Landsteiner University of Health Sciences. Recruiting at 2 sites in Austria. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Karl Landsteiner University of Health Sciences · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Hypoxia with a site in Austria — 2 open to participants now, 3 under way, none of them phase 3. Hypoxia · Austria.

Started
2025
the only one that year
No phase
7 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Karl Landsteiner University of Health Sciences

Among the 12 studies in Hypoxia with a site in Austria, this one is the only one that started in 2025, is one of 7 with no phase, and was the 11th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

2 of the 12 studies in Hypoxia with a site in Austria are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hypoxia with a site in Austria, or all of them as a file.
02

Study summary

Although sedation during endoscopy is sufficiently safe, desaturations are among the most common side effects of endoscopic retrograde cholangiopancreatography (ERCP) procedures, occurring in approximately 20-30% of cases. Sedation during endoscopy increases the complication rate, and a significant proportion of severe and serious side effects are respiratory/airway-related. However, most patients require sedation to complete the procedure and achieve adequate outcomes during therapeutic ERCP. Therefore, improved measures to increase ERCP safety are needed. Since the demand for anesthesia in many centers already (far) exceeds current capacities, performing additional ERCPs under general anesthesia is not an option. Innovative ways to improve cardiorespiratory monitoring or respiratory management during ERCP could offer a solution without significantly increasing costs. Fortunately, dedicated devices for respiratory management and/or monitoring during endoscopy already exist, but their impact on improving patient safety has not yet been well studied. Therefore, the aim of this prospective, randomized, open-label, non-interventional study is to investigate the effects of non-invasive airway management and respiratory monitoring devices on desaturation rate during endoscopic retrograde cholangiopancreatography.

For this purpose, 288 adult patients (male and female, 18+ years) undergoing ERCP for medical reasons will be enrolled and randomized to one of three groups: (i) airway management using positive airway pressure (PAP group), (ii) additional monitoring using capnography (capnography group), and (iii) a control group with standard monitoring/treatment (i.e., 2 L O2/min via nasal cannula) (control group). Patients are monitored during the ERCP procedure according to medical standards (non-invasive blood oxygen saturation measurement = SpO2, regular non-invasive blood pressure measurement, pulse), and all desaturation events (defined as an SpO2 \<85% for any duration according to guidelines) are recorded and treated according to guideline recommendations (the studies do not specify any measures for the (non-)treatment of desaturations). After the procedure, patients are followed (passively) for 30 days (review of medical records) to record late complications. The main outcome parameter is the comparison of the desaturation rate in the PAP versus the control group.

03

Conditions studied

  • Desaturation
  • Hypoxemia
  • ERCP

Browse trials for

Keywords

  • ERCP
  • Sedation-related adverse events
  • desaturation
  • trial
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • undergoing an interventional (intent) ERCP procedure
  • 18-99 years
  • Male or female
  • Nurse-administered sedation

Exclusion criteria

Exclusion Criteria:

  • History of allergic reaction to Propofol
  • Tracheostomy
  • Procedure requiring intubation, general anesthesia, or anesthesiologist backup (acute exacerbation of obstructive lung disease, acute congestive heart failure, supra-glottic or sub-glottic tumor, septic shock, e.g.) according to the endoscopist in charge
  • Pregnant patients
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
288 participants (estimated)

Study arms

  • Experimental
    PAP group

    Nasal PAP Ventilation System

    Device: Nasal PAP Ventilation System

  • Placebo comparator
    Control group

    Standard management consisting of low-flow oxygen through nasal cannula

    Device: Low Flow Oxygen

  • Active comparator
    Capnometry group

    capnometry and low-flow oxygen through nasal cannula

    Device: Low Flow Oxygen · Device: Capnometry

Interventions

  • DeviceNasal PAP Ventilation System

    medical devices that provide nasal positive airway pressure ventilation during endoscopy

    Also known as: nasal positive airway pressure

  • DeviceLow Flow Oxygen

    low flow oxygen though nasal cannula

  • DeviceCapnometry

    capnometry measurement

06

What researchers measure

Primary outcomes

  1. Difference in desaturation rate

    Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) of the PAP group vs. the standard management group

    Time frame: during endoscopic retrograde cholangio-pancreatography

Secondary outcomes

  1. Difference in desaturation rate

    Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) across the three groups

    Time frame: during endoscopic retrograde cholangio-pancreatography

  2. Difference in desaturation rate

    Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) of the capnometry group vs. the standard management group

    Time frame: during endoscopic retrograde cholangio-pancreatography

  3. Difference in desaturation rate

    Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) of the PAP group vs. the capnometry group

    Time frame: during endoscopic retrograde cholangio-pancreatography

  4. Rates of interventions for hypoxemic events

    Rates of interventions for hypoxemic events in the PAP group vs. the control group

    Time frame: during endoscopic retrograde cholangio-pancreatography

  5. Rates of interventions for hypoxemic events

    Rates of interventions for hypoxemic events in the PAP group vs. the capnometry group

    Time frame: during endoscopic retrograde cholangio-pancreatography

  6. Rates of interventions for hypoxemic events

    Rates of interventions for hypoxemic events in the capnometry group vs. the control group

    Time frame: during endoscopic retrograde cholangio-pancreatography

  7. Lowest SpO2

    Lowest SpO2 values across the three groups

    Time frame: during endoscopic retrograde cholangio-pancreatography

  8. Median procedure length

    Median procedure length (min) across the three groups

    Time frame: during endoscopic retrograde cholangio-pancreatography

  9. Satisfaction with sedation

    Endoscopist and patient satisfaction levels concerning the procedure on a Likert scale ("Satisfaction scale" 0-10, 0=worst, 10=best) across the three groups

    Time frame: Periprocedural

  10. Rate of sedation-related adverse events

    Rate of sedation-related adverse events across the three groups

    Time frame: during endoscopic retrograde cholangio-pancreatography

  11. Rate of SCOPE

    Rate of a combined endpoint of serious adverse events and clinical outcomes (SCOPE) across the three groups SCOPE (serious adverse events and clinical outcomes in procedural endoscopy) includes: 30-day all-cause mortality, cardiopulmonary resuscitation1, unplanned intubation or non-invasive ventilation1, single or multiorgan dysfunction due to an endoscopy-related adverse event (AGREE IVa/IVb), rescue or secondary intervention (endoscopic, surgical, or interventional radiology) due to an endoscopy-related adverse event (AGREE IIIa/b), post-ERCP pancreatitis, or target not reached (with necessity of a secondary procedure) 1 AE occurring after start of the procedure (first dose of sedation administered) until patient leaves recovery room.

    Time frame: from ERCP up to 30 days after procedure

07

Study locations

2 of 2 sites recruiting
  • Division of Gastroenterology and Hepatology, Department of Medicine, Medical University Graz
    Graz, Austria
    Recruiting
  • Department of Internal Medicine 2, University Hospital of St Pölten
    Sankt Pölten, 3100, Austria
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Nov 2026, 16 months after the start.

Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 16 months is above that.

Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 9, 2025
StartActual
Jul 7, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07056075
Lead sponsor
Karl Landsteiner University of Health Sciences
Responsible party
Dr. Julian Prosenz (Clinician Researcher, Karl Landsteiner University of Health Sciences) — Principal investigator
First posted
Jul 9, 2025
Start date
Jul 7, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion